Q4 2022 Results

Company overview Financial review 2023 priorities Appendix Novartis priorities for 2023 and beyond 1 Transforming to a pure-play IM company CONCLUSION Prioritizing pipeline in specific DAs to 5 high-value NMEs across our 5 core TAs 2 Focusing on 5 core TAs, technology platforms and the US 3 Establishing 9 key brands. with multi-$bn potential The most trusted and valued medicines company Continuing to deliver 6 improved financials Continuing with shareholder- 7 focused capital allocation 4 Improving R&D productivity (e.g. iptacopan, PluvictoⓇ) 48 Investor Relations | Q4 2022 Results Strengthening foundations - 8 ESG/Human Capital 1 NOVARTIS | Reimagining Medicine

View entire presentation